NeuroMetrix jumps on FDA breakthrough designation for its wearable neuro stimulator

NeuroMetrix

20/07/2021 15:13

** Shares of medical device maker  NURO.O  rise 32% to their
five-month high at $4.30 
    ** Co announces that its Quell device for treating symptoms
of fibromyalgia in adults has received breakthrough designation
from the U.S. Food and Drug Administration (FDA)  urn:newsml:reuters.com:*:nGNX6tRsSD
    ** Fibromyalgia is a common form of chronic pain accompanied
by fatigue, sleep, cognitive and mood disturbances
    ** Quell is a wearable nerve-stimulation device that is the
size of a credit card 
    ** Under the breakthrough device program, the FDA will
provide priority review and interactive communication regarding
device development, through to commercialization
    ** The use of Quell for fibromyalgia is investigational and
has not been cleared or approved by the U.S. FDA - co
    ** Up to Monday's close, stock had gained 3.2% YTD 

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))